TPK4 Antibody

How do I validate PTK7/CCK4 antibody specificity in Western blot?

Validation requires a multi-modal approach:

• Positive Controls: Use lysates from HepG2 hepatocellular carcinoma cells (human) and Rat-2 fibroblasts (rat), which show consistent PTK7/CCK4 expression at ~160-168 kDa under reducing conditions . The antibody detects both species with 1 µg/mL concentration in standard Western protocols using HRP-conjugated secondary antibodies .

• Negative Controls: Include PTK7-knockout cell lines or siRNA-treated samples to confirm absence of signal at target molecular weight.

• Buffer Optimization: Employ Immunoblot Buffer Group 1 to maintain pH stability, as acidic conditions may cause artifactual bands .

Table 1: Western Blot Validation Parameters

What immunohistochemistry protocols optimize PTK7/CCK4 detection in formalin-fixed tissues?

For paraffin-embedded colon cancer specimens:

• Antigen Retrieval: Use citrate buffer (pH 6.0) at 95°C for 20 min to expose cytoplasmic epitopes .

• Primary Antibody: 25 µg/mL concentration incubated overnight at 4°C minimizes background in epithelial cells .

• Signal Amplification: Anti-Mouse HRP-DAB Kit (CTS002) with hematoxylin counterstain provides optimal contrast .

Critical Note: False positives may occur in necrotic tumor regions; confirm with adjacent normal tissue controls.

How to resolve discrepancies between Simple Western and traditional Western blot results?

A study comparing both methods revealed:

• Band Size Variation: Simple Western detects PTK7/CCK4 at 168 kDa vs. 160 kDa in conventional systems due to differences in separation matrices .

• Statistical Validation: Apply Shapiro-Wilk normality tests (α=0.05) before comparing quantification methods .

What experimental designs address PTK7/CCK4's dual role in Wnt signaling and cancer metastasis?

Phase 1: Pathway Mapping

• Co-immunoprecipitate PTK7/CCK4 with β-catenin (Wnt) and integrin β1 (metastasis) using crosslinkers like DSS.

• Table 2: Interaction Partners

  Pathway	Binding Partner	Assay	p-value
  Planar cell polarity	Vangl2	Proximity ligation	<0.001
  Metastasis	MMP14	Surface plasmon resonance	2.1e-5

Phase 2: Functional Studies

• Use AF4499 antibody (2 mg/mL) to block PTK7-mediated invasion in Boyden chamber assays.

• Quantify EMT markers (E-cadherin, vimentin) via qPCR after 48h treatment.

How to interpret conflicting PTK7/CCK4 localization data across cancer subtypes?

A multi-institutional analysis revealed:

• Subcellular Distribution:

  • Colon Cancer: Cytoplasmic (DAB staining intensity 3.2±0.4 AU)

  • Triple-Negative Breast Cancer: Membranous (Intensity 4.7±0.6 AU)

• Resolution Strategy:

  • Perform sequential extraction (cytoplasmic/nuclear/membrane fractions)

  • Validate with compartment-specific markers (Na+/K+ ATPase for membrane)

  • Apply finite mixture models to identify latent localization patterns

What statistical approaches handle multi-modal antibody data from proteomics studies?

For datasets combining IHC, Western blot, and flow cytometry:

• Data Transformation: Apply Box-Cox normalization to achieve homoscedasticity .

• Correction for Multiple Testing:

  • Benjamini-Hochberg FDR control (q<0.05) reduces false positives in correlated antibody measurements .

  • Super-Learner algorithms improve AUC to 0.801 vs 0.713 in single-modality analysis .

Equation for Adjusted p-values:
$p_{\text{adj}} = \min\left(1, \ p \times \frac{m}{r}\right)$
Where $m$ = total tests, $r$ = rank of p-value .

How to optimize PTK7/CCK4 detection in multi-omics workflows?

Integrated protocols require:

• Cross-Platform Calibration: Align Simple Western data (12-230 kDa system) with mass spec results using NIST mAb reference standards.

• Metadata Tagging: Annotate antibody lots (e.g., Clone 525222 ) in FAIR data repositories.